Experiments carried out by other researchers demonstrated that splicing factor SRSF2 mutations induced dramatic inhibition of proliferation and G2/M phase arrest in primary human CD34+ cells and HEK293T cells (52, 53), while these deleterious effects did not occur in SRSF2 mutated K562 cells or SRSF2-P95H myelodysplastic syndromes mouse models (52, 54, 55). The gene discussed is CD34; the disease is myelodysplastic syndrome.